International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
暂无分享,去创建一个
[1] Janet B W Williams,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[2] Xiaowei Jin,et al. Inosine Binds to A 3 Adenosine Receptors and Stimulates Mast Cell Degranulation , 2013 .
[3] E. Walker,et al. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[4] Kenneth A Jacobson,et al. Recent developments in adenosine receptor ligands and their potential as novel drugs. , 2011, Biochimica et biophysica acta.
[5] K. Varani,et al. A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. , 2011, American journal of respiratory and critical care medicine.
[6] K. Varani,et al. Adenosine receptors in health and disease. , 2011, Advances in pharmacology.
[7] C. Freitag,et al. Adenosine A(2A) receptor gene: evidence for association of risk variants with panic disorder and anxious personality. , 2010, Journal of psychiatric research.
[8] P. White,et al. Delineating the Mode of Action of Adenosine A1 Receptor Allosteric Modulators , 2010, Molecular Pharmacology.
[9] K. Jacobson,et al. Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay. , 2010, Biochemical pharmacology.
[10] B. Fredholm,et al. Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[11] K. Jacobson,et al. Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. , 2010, Ophthalmology.
[12] Wei Liu,et al. Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture , 2010, Nature Neuroscience.
[13] B. Fredholm,et al. Adenosine A1 receptors and vascular reactivity , 2010, Acta physiologica.
[14] K. Varani,et al. Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes , 2010, British journal of pharmacology.
[15] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[16] Judy Lin,et al. Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. , 2010, Journal of medicinal chemistry.
[17] S. Chandra,et al. Synthesis and biological evaluation of 99mTc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies , 2010 .
[18] Sergio Paredes,et al. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists. , 2010, Bioorganic & medicinal chemistry letters.
[19] B. Fredholm,et al. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. , 2010, Arthritis and rheumatism.
[20] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[21] K. Jacobson,et al. Adenosine A3 Receptors in Muscle Protection , 2010 .
[22] Thea Mulder-Krieger,et al. The endocannabinoid 2-arachidonylglycerol is a negative allosteric modulator of the human A3 adenosine receptor. , 2010, Biochemical pharmacology.
[23] Ruben Abagyan,et al. Structure-Based Discovery of Novel Chemotypes for Adenosine A 2 A Receptor Antagonists , 2010 .
[24] J. Giraldo,et al. The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. , 2010, Trends in pharmacological sciences.
[25] K. Klotz,et al. Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor. , 2009, Journal of Medicinal Chemistry.
[26] A. Pinna. Novel investigational adenosine A2A receptor antagonists for Parkinson's disease , 2009, Expert opinion on investigational drugs.
[27] Antagonists of the Human A2A Receptor. Part 5. Highly Bio-Available Pyrimidine-4-carboxamides. , 2009 .
[28] A. Iskandrian,et al. Regadenoson: a new myocardial stress agent. , 2009, Journal of the American College of Cardiology.
[29] Michael R. Elliott,et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance , 2009, Nature.
[30] J. Linden,et al. Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[31] Marta Filizola,et al. Modern homology modeling of G-protein coupled receptors: which structural template to use? , 2009, Journal of medicinal chemistry.
[32] H. Kaneko,et al. A highly conserved tryptophan residue in the fourth transmembrane domain of the A1 adenosine receptor is essential for ligand binding but not receptor homodimerization , 2009, Journal of neurochemistry.
[33] K. Fuxe,et al. Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors* , 2009, The Journal of Biological Chemistry.
[34] Arthur Christopoulos,et al. Allosteric modulators of the adenosine A1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3-benzoylthiophenes. , 2009, Journal of medicinal chemistry.
[35] J. F. Chen,et al. Adenosine, adenosine A 2A antagonists, and Parkinson's disease. , 2009, Parkinsonism & related disorders.
[36] Masahiko Watanabe,et al. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher‐order oligomers in living cells , 2009, Journal of neurochemistry.
[37] S. Lévy,et al. Head-up tilt induced syncope and adenosine A2A receptor gene polymorphism. , 2009, European heart journal.
[38] Charles L. Brooks,et al. Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008 , 2009, Nature Reviews Drug Discovery.
[39] Dov Barak,et al. Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. , 2009, Journal of medicinal chemistry.
[40] Thomas Borrmann,et al. 1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. , 2009, Journal of medicinal chemistry.
[41] K. Jacobson,et al. Novel 2- and 4-substituted 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric modulators of the A3 adenosine receptor. , 2009, Journal of medicinal chemistry.
[42] Bruno Antonny,et al. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. , 2009, Trends in pharmacological sciences.
[43] B. Fredholm,et al. Physiological roles of A1 and A2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. , 2009, American journal of physiology. Heart and circulatory physiology.
[44] Dharini van der Hoeven,et al. Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog , 2009, Journal of Pharmacology and Experimental Therapeutics.
[45] R. Tsien,et al. The Dynamic Control of Kiss-And-Run and Vesicular Reuse Probed with Single Nanoparticles , 2009, Science.
[46] Michel Bouvier,et al. Building a new conceptual framework for receptor heteromers. , 2009, Nature chemical biology.
[47] K. Min,et al. Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. , 2009, Respiratory medicine.
[48] B. Fredholm,et al. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. , 2009, Journal of applied physiology.
[49] Thea Mulder-Krieger,et al. A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. , 2009, Journal of medicinal chemistry.
[50] A. Knight,et al. Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. , 2009, Journal of medicinal chemistry.
[51] P. Fishman,et al. The anti-inflammatory target A(3) adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. , 2009, Cellular immunology.
[52] K. Jacobson. Introduction to adenosine receptors as therapeutic targets. , 2009, Handbook of experimental pharmacology.
[53] Arthur Christopoulos,et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders , 2009, Nature Reviews Drug Discovery.
[54] B. Fredholm,et al. Perinatal Caffeine, Acting on Maternal Adenosine A1 Receptors, Causes Long-Lasting Behavioral Changes in Mouse Offspring , 2008, PloS one.
[55] B. Fredholm,et al. Adenosine in the tuberomammillary nucleus inhibits the histaminergic system via A1 receptors and promotes non-rapid eye movement sleep , 2008, Proceedings of the National Academy of Sciences.
[56] Adriaan P IJzerman,et al. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models , 2009, BMC pharmacology.
[57] Pierre-Alexandre Vidi,et al. Adenosine A2A receptors assemble into higher‐order oligomers at the plasma membrane , 2008, FEBS letters.
[58] F. Ciruela,et al. Plasma membrane diffusion of G protein-coupled receptor oligomers. , 2008, Biochimica et biophysica acta.
[59] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[60] E. Elzein,et al. A1 adenosine receptor agonists and their potential therapeutic applications , 2008 .
[61] R. Hauser,et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations , 2008, Movement disorders : official journal of the Movement Disorder Society.
[62] B. Fredholm,et al. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. , 2008, European journal of pharmacology.
[63] J. Linden,et al. Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. , 2008, American journal of physiology. Heart and circulatory physiology.
[64] F. Ciruela,et al. Detection of Heteromers Formed by Cannabinoid CB1, Dopamine D2, and Adenosine A2A G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer , 2008, TheScientificWorldJournal.
[65] C. O'connor,et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. , 2008, Journal of cardiac failure.
[66] J. P. Petzer,et al. Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. , 2008, Bioorganic & medicinal chemistry.
[67] F. Ciruela,et al. Detection of higher‐order G protein‐coupled receptor oligomers by a combined BRET–BiFC technique , 2008, FEBS letters.
[68] Pierre-Alexandre Vidi,et al. Ligand-Dependent Oligomerization of Dopamine D2 and Adenosine A2A Receptors in Living Neuronal Cells , 2008, Molecular Pharmacology.
[69] K. Varani,et al. Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. , 2008, Journal of medicinal chemistry.
[70] Yoko Shibata,et al. Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor , 2008, Proceedings of the National Academy of Sciences.
[71] Anna Maria Bianucci,et al. N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors. , 2008, European journal of medicinal chemistry.
[72] Gemma Navarro,et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET , 2008, Nature Methods.
[73] B. Fredholm,et al. Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. , 2008, The Journal of allergy and clinical immunology.
[74] I. Bruce,et al. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX , 2008, Rheumatology.
[75] M. Stacy,et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease , 2008, Neurology.
[76] C. Ledent,et al. Up-regulation of A 2B adenosine receptor in A 2A adenosine receptor knockout mouse coronary artery. , 2008, Journal of molecular and cellular cardiology.
[77] K. Jacobson,et al. Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists. , 2008, Bioorganic & medicinal chemistry letters.
[78] J. Tsien,et al. A Critical Role of the Adenosine A2A Receptor in Extrastriatal Neurons in Modulating Psychomotor Activity as Revealed by Opposite Phenotypes of Striatum and Forebrain A2A Receptor Knock-Outs , 2008, The Journal of Neuroscience.
[79] David A. Lustig,et al. Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. , 2008, Journal of medicinal chemistry.
[80] P. Tuite,et al. Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005) , 2008, Annals of neurology.
[81] J. Badner,et al. Association between ADORA2A and DRD2 Polymorphisms and Caffeine-Induced Anxiety , 2008, Neuropsychopharmacology.
[82] Krzysztof Palczewski,et al. Efficient Coupling of Transducin to Monomeric Rhodopsin in a Phospholipid Bilayer* , 2008, Journal of Biological Chemistry.
[83] I. Biaggioni,et al. Effect of A2B Adenosine Receptor Gene Ablation on Adenosine-Dependent Regulation of Proinflammatory Cytokines , 2008, Journal of Pharmacology and Experimental Therapeutics.
[84] M. Koupenova,et al. The A2b adenosine receptor protects against vascular injury , 2008, Proceedings of the National Academy of Sciences.
[85] G. Gross,et al. The A3 Adenosine Receptor Agonist CP-532,903 [N6-(2,5-Dichlorobenzyl)-3′-aminoadenosine-5′-N-methylcarboxamide] Protects against Myocardial Ischemia/Reperfusion Injury via the Sarcolemmal ATP-Sensitive Potassium Channel , 2008, Journal of Pharmacology and Experimental Therapeutics.
[86] B. Fredholm,et al. A1 receptor deficiency causes increased insulin and glucagon secretion in mice. , 2007, Biochemical pharmacology.
[87] B. Fredholm,et al. 1,3,7-Trimethylxanthine (Caffeine) May Exacerbate Acute Inflammatory Liver Injury by Weakening the Physiological Immunosuppressive Mechanism1 , 2007, The Journal of Immunology.
[88] F. Pedata,et al. Adenosine A2A receptors and brain injury: Broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation , 2007, Progress in Neurobiology.
[89] B. Fredholm,et al. Adenosine dysfunction in astrogliosis: cause for seizure generation? , 2007, Neuron glia biology.
[90] K. Ardlie,et al. Polymorphisms in Adenosine Receptor Genes are Associated with Infarct Size in Patients with Ischemic Cardiomyopathy , 2007, Clinical pharmacology and therapy.
[91] J. Downey,et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. , 2007, Journal of molecular and cellular cardiology.
[92] F. Popescu,et al. A review of antisense therapeutic interventions for molecular biological targets in asthma , 2007, Biologics : targets & therapy.
[93] B. Hocher,et al. The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure , 2007, British journal of pharmacology.
[94] Joseph Shiloach,et al. Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction , 2007, Proceedings of the National Academy of Sciences.
[95] K. Ley,et al. Therapeutic Anti-Inflammatory Effects of Myeloid Cell Adenosine Receptor A2a Stimulation in Lipopolysaccharide-Induced Lung Injury1 , 2007, The Journal of Immunology.
[96] Qingming Luo,et al. Regulated ATP release from astrocytes through lysosome exocytosis , 2007, Nature Cell Biology.
[97] X. Hua,et al. Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. , 2007, American journal of physiology. Lung cellular and molecular physiology.
[98] Carolyn M. McClaskey,et al. A1 adenosine receptors play an essential role in protecting the embryo against hypoxia , 2007, Proceedings of the National Academy of Sciences.
[99] Geoffrey D. Clarke,et al. Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice , 2007, PAIN.
[100] B. Fredholm,et al. Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes in the antilipolytic actions of PGE2 and nicotinic acid , 2007, Acta physiologica.
[101] B. Fredholm,et al. Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors , 2007, Acta physiologica.
[102] M. Loza,et al. Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. , 2007, Journal of medicinal chemistry.
[103] Richard N. Zare,et al. A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein , 2007, Proceedings of the National Academy of Sciences.
[104] H. Landolt,et al. A Genetic Variation in the Adenosine A2A Receptor Gene (ADORA2A) Contributes to Individual Sensitivity to Caffeine Effects on Sleep , 2007, Clinical pharmacology and therapeutics.
[105] C. Ledent,et al. Cardioprotection by Ecto-5′-Nucleotidase (CD73) and A2B Adenosine Receptors , 2007, Circulation.
[106] F. Ciruela,et al. Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids , 2007, Neuropsychopharmacology.
[107] Michel Bouvier,et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers , 2007, Pharmacological Reviews.
[108] K. Klotz,et al. [3H]HEMADO--a novel tritiated agonist selective for the human adenosine A3 receptor. , 2007, European journal of pharmacology.
[109] K. Varani,et al. Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. , 2007, Journal of medicinal chemistry.
[110] X. Hua,et al. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor , 2007, The Journal of Experimental Medicine.
[111] X. Hua,et al. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor , 2007, The Journal of experimental medicine.
[112] A. IJzerman,et al. 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. , 2007, Journal of medicinal chemistry.
[113] P. Baraldi,et al. Allosteric enhancers for A1 adenosine receptor. , 2007, Mini reviews in medicinal chemistry.
[114] H. Nakata,et al. Functions of heteromeric association between adenosine and P2Y receptors , 2007, Journal of Molecular Neuroscience.
[115] C. Müller,et al. Blocking striatal adenosine A2A receptors: a new strategy for basal ganglia disorders. , 2007, Recent patents on CNS drug discovery.
[116] H. Nakata,et al. Regulation of pharmacology by hetero-oligomerization between A1 adenosine receptor and P2Y2 receptor. , 2006, Biochemical and biophysical research communications.
[117] Linda Yip,et al. ATP Release Guides Neutrophil Chemotaxis via P2Y2 and A3 Receptors , 2006, Science.
[118] G. Gross,et al. Cl-IB-MECA [2-Chloro-N6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] Reduces Ischemia/Reperfusion Injury in Mice by Activating the A Adenosine Receptor , 2006, Journal of Pharmacology and Experimental Therapeutics.
[119] B. Ransom,et al. Functional connexin “hemichannels”: A critical appraisal , 2006, Glia.
[120] Yaqin Xu,et al. Myocardial Infarct–Sparing Effect of Adenosine A2A Receptor Activation Is due to Its Action on CD4+ T Lymphocytes , 2006, Circulation.
[121] Xiaowei Jin,et al. Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. , 2006, Journal of medicinal chemistry.
[122] Liqun Yu,et al. Adenosine A2A Receptors in Bone Marrow-Derived Cells But Not in Forebrain Neurons Are Important Contributors to 3-Nitropropionic Acid-Induced Striatal Damage as Revealed by Cell-Type-Selective Inactivation , 2006, The Journal of Neuroscience.
[123] P. MacDonald,et al. Release of small transmitters through kiss-and-run fusion pores in rat pancreatic beta cells. , 2006, Cell metabolism.
[124] W. Oyen,et al. Caffeine prevents protection in two human models of ischemic preconditioning. , 2006, Journal of the American College of Cardiology.
[125] K. Klotz,et al. Improving Potency, Selectivity, and Water Solubility of Adenosine A1 Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones , 2006, ChemMedChem.
[126] Seiko F. Okada,et al. Physiological Regulation of ATP Release at the Apical Surface of Human Airway Epithelia*♦ , 2006, Journal of Biological Chemistry.
[127] Stephen A Baldwin,et al. Nucleoside transporters: from scavengers to novel therapeutic targets. , 2006, Trends in pharmacological sciences.
[128] C. Müller,et al. Characterization of human and rodent native and recombinant adenosine A2B receptors by radioligand binding studies , 2006, Purinergic Signalling.
[129] M. Koupenova,et al. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. , 2006, The Journal of clinical investigation.
[130] B. Fredholm,et al. Adenosine A1 receptors are crucial in keeping an epileptic focus localized , 2006, Experimental Neurology.
[131] Johannes Brussee,et al. Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. , 2006, Journal of medicinal chemistry.
[132] Xiaowei Jin,et al. Norbornyllactone-substituted xanthines as adenosine A(1) receptor antagonists. , 2006, Bioorganic & medicinal chemistry.
[133] A. Tucker,et al. The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs. , 2006, The Biochemical journal.
[134] B. Fredholm,et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. , 2006, American journal of physiology. Heart and circulatory physiology.
[135] G. Nikolakopoulos,et al. 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. , 2006, Bioorganic & medicinal chemistry.
[136] P. Kochanek,et al. Adenosine A1 Receptor Knockout Mice Develop Lethal Status Epilepticus after Experimental Traumatic Brain Injury , 2006, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[137] A. IJzerman,et al. Allosteric modulation, thermodynamics and binding to wild‐type and mutant (T277A) adenosine A1 receptors of LUF5831, a novel nonadenosine‐like agonist , 2006, British journal of pharmacology.
[138] K. Varani,et al. Synthesis and biological characterization of [3H] (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer. , 2006, Bioorganic & medicinal chemistry letters.
[139] K. Jacobson,et al. Adenosine receptors as therapeutic targets , 2006, Nature Reviews Drug Discovery.
[140] Geoffrey Burnstock,et al. Historical review: ATP as a neurotransmitter. , 2006, Trends in pharmacological sciences.
[141] Graeme Milligan,et al. Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1–A2A Receptor Heteromers , 2006, The Journal of Neuroscience.
[142] T. Schwartz,et al. Ago-Allosteric Modulation and Other Types of Allostery in Dimeric 7TM Receptors , 2006, Journal of receptor and signal transduction research.
[143] P. Sexton,et al. Effects of urea pretreatment on the binding properties of adenosine A1 receptors , 2005, British journal of pharmacology.
[144] J. Linden,et al. Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. , 2005, The Biochemical journal.
[145] H. Landolt,et al. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[146] Giovanni Piersanti,et al. 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. , 2005, Journal of medicinal chemistry.
[147] S. Doggrell. BG-9928 (Biogen Idec). , 2005, Current opinion in investigational drugs.
[148] M. Chordia,et al. 6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A1 adenosine receptor agonist allosteric enhancers having improved potency. , 2005, Journal of medicinal chemistry.
[149] B. Fredholm,et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine , 2005, Nature Neuroscience.
[150] M. le Maire,et al. Monomeric G-protein-coupled receptor as a functional unit. , 2005, Biochemistry.
[151] Kenneth A Jacobson,et al. Allosteric modulation of the adenosine family of receptors. , 2005, Mini reviews in medicinal chemistry.
[152] J. Linden,et al. A Crucial Role for Forebrain Adenosine A2A Receptors in Amphetamine Sensitization , 2005, Neuropsychopharmacology.
[153] S. Robson,et al. Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. , 2005, Seminars in thrombosis and hemostasis.
[154] A. IJzerman,et al. A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. , 2005, Journal of medicinal chemistry.
[155] A. IJzerman,et al. Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. , 2005, Bioorganic & medicinal chemistry.
[156] R. Leurs,et al. A "locked-on," constitutively active mutant of the adenosine A1 receptor. , 2005, European journal of pharmacology.
[157] J. Schnermann,et al. Role of A1 adenosine receptors in regulation of vascular tone. , 2005, American journal of physiology. Heart and circulatory physiology.
[158] B. Fredholm,et al. Increased nociceptive response in mice lacking the adenosine A1 receptor , 2005, Pain.
[159] K. Fuxe,et al. Adenosine A2A Receptor and Dopamine D3 Receptor Interactions: Evidence of Functional A2A/D3 Heteromeric Complexes , 2005, Molecular Pharmacology.
[160] Courtney M. Lappas,et al. A2A Adenosine Receptor Induction Inhibits IFN-γ Production in Murine CD4+ T Cells1 , 2005, The Journal of Immunology.
[161] Matthew R. Jones,et al. Animal models for the study of adenosine receptor function , 2005, Journal of cellular physiology.
[162] B. Fredholm,et al. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. , 2005, Annual review of pharmacology and toxicology.
[163] Courtney M. Lappas,et al. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. , 2005, Journal of immunology.
[164] C. Müller,et al. Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats , 2005, Psychopharmacology.
[165] S. Colgan,et al. Crucial Role for Ecto-5′-Nucleotidase (CD73) in Vascular Leakage during Hypoxia , 2004, The Journal of experimental medicine.
[166] K. Ley,et al. Targeted Disruption of cd73/Ecto-5′-Nucleotidase Alters Thromboregulation and Augments Vascular Inflammatory Response , 2004, Circulation research.
[167] B. Fredholm,et al. Adenosine A1 receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia , 2004 .
[168] A. IJzerman,et al. New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. , 2004, Journal of medicinal chemistry.
[169] Susan E Hodge,et al. Evidence for Genetic Linkage Between a Polymorphism in the Adenosine 2A Receptor and Panic Disorder , 2004, Neuropsychopharmacology.
[170] K. Varani,et al. Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. , 2004, Journal of medicinal chemistry.
[171] C. Müller,et al. Antinociceptive Effects of Novel A2B Adenosine Receptor Antagonists , 2004, Journal of Pharmacology and Experimental Therapeutics.
[172] K. Fuxe,et al. Homodimerization of adenosine A2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer , 2003, Journal of neurochemistry.
[173] K. Klotz,et al. Comparison of A1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling , 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.
[174] J. Ramachandran,et al. Structure and Function of G Protein Coupled Receptors , 1990, Pharmaceutical Research.
[175] Hiroshi Kase,et al. Industry forum: Progress in pursuit of therapeutic A2A antagonists , 2003, Neurology.
[176] B. Fredholm,et al. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor , 2003, Journal of Sleep Research.
[177] Francesca Fanelli,et al. Adenosine A2A-Dopamine D2 Receptor-Receptor Heteromerization , 2003, Journal of Biological Chemistry.
[178] C. Müller,et al. Adenosine receptor agonists: from basic medicinal chemistry to clinical development , 2003, Expert opinion on emerging drugs.
[179] T Kendall Harden,et al. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. , 2003, Molecular pharmacology.
[180] J. Fozard,et al. Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. , 2003, European journal of pharmacology.
[181] R. J. Hill,et al. Novel N6-substituted adenosine 5'-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. , 2003, American journal of physiology. Heart and circulatory physiology.
[182] C. Saper,et al. Focal Deletion of the Adenosine A1 Receptor in Adult Mice Using an Adeno-Associated Viral Vector , 2003, The Journal of Neuroscience.
[183] H. Nakata,et al. Oligomerization of adenosine A2A and dopamine D2 receptors in living cells. , 2003, Biochemical and biophysical research communications.
[184] P. Sand,et al. Association Between A2a Receptor Gene Polymorphisms and Caffeine-Induced Anxiety , 2003, Neuropsychopharmacology.
[185] A. Ohta,et al. Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. , 2003, Biochemical pharmacology.
[186] J. Eisenach,et al. Allosteric Adenosine Receptor Modulation Reduces Hypersensitivity Following Peripheral Inflammation by a Central Mechanism , 2003, Journal of Pharmacology and Experimental Therapeutics.
[187] Kenneth A Jacobson,et al. Identification of essential residues involved in the allosteric modulation of the human A(3) adenosine receptor. , 2003, Molecular pharmacology.
[188] R. Boucher,et al. Ecto 5′-Nucleotidase and Nonspecific Alkaline Phosphatase , 2003, The Journal of Biological Chemistry.
[189] Adriaan P IJzerman,et al. N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. , 2003, Journal of medicinal chemistry.
[190] K. Jacobson,et al. Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. , 2003, Biochemical Pharmacology.
[191] K. Jacobson,et al. 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A3 adenosine receptors. , 2003, Bioorganic & medicinal chemistry.
[192] M. Maj,et al. Formalin-induced pain and μ-opioid receptor density in brain and spinal cord are modulated by A1 and A2 a adenosine agonists in mice , 2002, Brain Research.
[193] Y. Kuroda,et al. Hetero‐oligomerization of adenosine A1 receptors with P2Y1 receptors in rat brains , 2002, FEBS letters.
[194] B. Fredholm,et al. Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors , 2002, Neuroscience.
[195] Dirk Bier,et al. Synthesis and evaluation of no-carrier-added 8-cyclopentyl-3-(3-[(18)F]fluoropropyl)-1-propylxanthine ([(18)F]CPFPX): a potent and selective A(1)-adenosine receptor antagonist for in vivo imaging. , 2002, Journal of medicinal chemistry.
[196] B. Fredholm,et al. Modulation of Hippocampal Glutamatergic Transmission by ATP Is Dependent on Adenosine A1 Receptors , 2002, Journal of Pharmacology and Experimental Therapeutics.
[197] L. Agnati,et al. Interactions among adenosine deaminase, adenosine A1 receptors and dopamine D1 receptors in stably cotransfected fibroblast cells and neurons , 2002, Neuroscience.
[198] Kenneth A Jacobson,et al. Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[199] Adriaan P IJzerman,et al. Selective allosteric enhancement of agonist binding and function at human A3 adenosine receptors by a series of imidazoquinoline derivatives. , 2002, Molecular pharmacology.
[200] K. Klotz,et al. N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. , 2002, Journal of medicinal chemistry.
[201] H. Yee,et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. , 2002, The American journal of pathology.
[202] J. Shimada,et al. KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. , 2002, European journal of pharmacology.
[203] K. Jacobson,et al. Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. , 2002, Journal of medicinal chemistry.
[204] Michele Zoli,et al. Coaggregation, Cointernalization, and Codesensitization of Adenosine A2A Receptors and Dopamine D2Receptors* , 2002, The Journal of Biological Chemistry.
[205] B. Fowler,et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[206] C. Müller,et al. 1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. , 2002, Journal of medicinal chemistry.
[207] Christa E. Müller,et al. [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1h-imidazo[2,1-i]-purin-5- one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors , 2002 .
[208] C. Ledent,et al. Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. , 2002, American journal of physiology. Heart and circulatory physiology.
[209] C. Müller,et al. [(3)H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i]-purin-5-one ([(3)H]PSB-11), a novel high-affinity antagonist radioligand for human A(3) adenosine receptors. , 2002, Bioorganic & medicinal chemistry letters.
[210] A. Ohta,et al. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage , 2001, Nature.
[211] B. Fredholm,et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. , 2001, Pharmacological reviews.
[212] K. Jacobson,et al. Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives. , 2001, Molecular pharmacology.
[213] B. Fredholm,et al. Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[214] Tianxin Yang,et al. Mediation of tubuloglomerular feedback by adenosine: Evidence from mice lacking adenosine 1 receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[215] B. Fredholm,et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[216] H. Nakata,et al. Heteromeric association creates a P2Y-like adenosine receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[217] M. Schwarzschild,et al. Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[218] W. Bao,et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. , 2001, Journal of molecular and cellular cardiology.
[219] M. Low,et al. The role of the D2 dopamine receptor (D2R) in A2A adenosine receptor (A2AR)-mediated behavioral and cellular responses as revealed by A2A and D2 receptor knockout mice , 2001 .
[220] B. Fredholm,et al. Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. , 2001, Biochemical pharmacology.
[221] A. IJzerman,et al. Differential effects of the allosteric enhancer (2-amino-4,5-dimethyl-trienyl)[3-trifluoromethyl) phenyl]methanone (PD81,723) on agonist and antagonist binding and function at the human wild-type and a mutant (T277A) adenosine A1 receptor. , 2001, Biochemical pharmacology.
[222] J. F. Chen,et al. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[223] R. Boucher,et al. Constitutive Release of ATP and Evidence for Major Contribution of Ecto-nucleotide Pyrophosphatase and Nucleoside Diphosphokinase to Extracellular Nucleotide Concentrations* , 2000, The Journal of Biological Chemistry.
[224] A. IJzerman,et al. Allosteric modulation of A(2A) adenosine receptors by amiloride analogues and sodium ions. , 2000, Biochemical pharmacology.
[225] I. Lampronti,et al. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of A1-adenosine receptor. , 2000, Bioorganic & medicinal chemistry letters.
[226] B. Fredholm,et al. Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. , 2000, Molecular pharmacology.
[227] E I Canela,et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[228] C. Müller,et al. Binding of [3H]MSX-2 (3-(3-hydroxypropyl)-7-methyl-8-(m-methoxystyryl)-1-propargylxanthine) to rat striatal membranes--a new, selective antagonist radioligand for A(2A) adenosine receptors. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[229] A. IJzerman,et al. Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. , 2000, Journal of medicinal chemistry.
[230] A. IJzerman,et al. Elucidation of structure–activity relationships of 2‐amino‐3‐benzoylthiophenes: Study of their allosteric enhancing vs. antagonistic activity on adenosine A1 receptors , 2000 .
[231] Marc Parmentier,et al. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A2A receptors , 2000, British journal of pharmacology.
[232] D. Standaert,et al. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors , 2000, Neuroscience.
[233] K. Jacobson,et al. Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. , 2000, Journal of medicinal chemistry.
[234] Beverly H. Koller,et al. Disruption of the A3 Adenosine Receptor Gene in Mice and Its Effect on Stimulated Inflammatory Cells* , 2000, The Journal of Biological Chemistry.
[235] M. Jacobson,et al. Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. , 2000, The Journal of clinical investigation.
[236] K. Klotz,et al. Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.
[237] C. Müller. A2A adenosine receptor antagonists - future drugs for Parkinson's disease? , 2000 .
[238] C. E. Műller. Adenosine receptor ligands-recent developments part I. Agonists. , 2000, Current medicinal chemistry.
[239] P. Svenningsson,et al. Distribution, biochemistry and function of striatal adenosine A2A receptors , 1999, Progress in Neurobiology.
[240] M. Moskowitz,et al. A2A Adenosine Receptor Deficiency Attenuates Brain Injury Induced by Transient Focal Ischemia in Mice , 1999, The Journal of Neuroscience.
[241] Patricia D. Christie,et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.
[242] A. IJzerman,et al. Allosteric modulation of the adenosine A(1) receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. , 1999, Journal of medicinal chemistry.
[243] K. Jacobson,et al. Acyl‐hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors , 1999 .
[244] K. Jacobson,et al. 1,3‐dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors , 1999, Drug development research.
[245] B. Fredholm,et al. Signaling via A2A adenosine receptor in four PC12 cell clones , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[246] A. IJzerman,et al. A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. , 1998, Journal of medicinal chemistry.
[247] C. Martini,et al. 2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. , 1998, Journal of medicinal chemistry.
[248] M. Blackburn,et al. Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined Immunodeficiency* , 1998, The Journal of Biological Chemistry.
[249] K. Fuxe,et al. Adenosine A1 Receptor-mediated Modulation of Dopamine D1 Receptors in Stably Cotransfected Fibroblast Cells* , 1998, The Journal of Biological Chemistry.
[250] M. Nöthen,et al. Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease , 1998, Molecular Psychiatry.
[251] B. Fredholm,et al. Comparative pharmacology of human adenosine receptor subtypes – characterization of stably transfected receptors in CHO cells , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[252] R. K. Shepherd,et al. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. , 1997, The Journal of clinical investigation.
[253] J. Linden,et al. Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. , 1997, Molecular pharmacology.
[254] Hiroshi Kase,et al. Adenosine A2A antagonists with potent anti-cataleptic activity , 1997 .
[255] S. Schiffmann,et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor , 1997, Nature.
[256] R. Lum,et al. Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbonyl)]-xanthine. , 1997, Journal of medicinal chemistry.
[257] A. IJzerman,et al. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding. , 1996, Molecular pharmacology.
[258] C. Romano,et al. Metabotropic Glutamate Receptor 5 Is a Disulfide-linked Dimer* , 1996, The Journal of Biological Chemistry.
[259] B. Stein,et al. Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications , 1996, Current Pharmaceutical Design.
[260] S. Lazareno,et al. The affinity of adenosine for the high- and low-affinity states of the human adenosine A1 receptor. , 1996, European journal of pharmacology.
[261] G. Firestein,et al. Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. , 1996, Journal of immunology.
[262] F. Ciruela,et al. Adenosine Deaminase Interacts with A1 Adenosine Receptors in Pig Brain Cortical Membranes , 1996, Journal of neurochemistry.
[263] J. Wess,et al. Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.
[264] L. Belardinelli,et al. Adenosine and Adenine Nucleotides: From Molecular Biology to Integrative Physiology , 2012, Springer US.
[265] F. Ciruela,et al. Immunological identification of A1 adenosine receptors in brain cortex , 1995, Journal of neuroscience research.
[266] K. Jacobson,et al. "Cleavable trifunctional" approach to receptor affinity labeling: chemical regeneration of binding to A1-adenosine receptors. , 1995, Bioconjugate chemistry.
[267] K. Jacobson,et al. A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.
[268] G Burnstock,et al. Nomenclature and Classification of Purinoceptors* , 2005 .
[269] C. Müller,et al. Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A1- and A2-adenosine receptor antagonists. , 1994, Journal of medicinal chemistry.
[270] J. Daly,et al. Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. , 1994, Biochemical pharmacology.
[271] Dc Washington. Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. , 1994 .
[272] J. Linden,et al. Molecular cloning and characterization of the human A3 adenosine receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[273] C. Müller,et al. Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. , 1993, Journal of medicinal chemistry.
[274] K. Jacobson,et al. Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists. , 1993, Journal of medicinal chemistry.
[275] J. Daly,et al. Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. , 1993, Pharmacology.
[276] S. Rivkees,et al. RFL9 encodes an A2b-adenosine receptor. , 1992, Molecular endocrinology.
[277] G. Stiles,et al. Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[278] B. Fredholm,et al. Magnesium‐Dependent Enhancement of Endogenous Agonist Binding to A1 Adenosine Receptors: A Complicating Factor in Quantitative Autoradiography , 1992, Journal of neurochemistry.
[279] A. IJzerman,et al. 1H-Imidazo(4,5-c)quinolin-4-amines: Novel Non-Xanthine Adenosine Antagonists. , 1991 .
[280] M. Parmentier,et al. The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. , 1991, The EMBO journal.
[281] C. Müller,et al. Caffeine analogs: structure-activity relationships at adenosine receptors. , 1991, Pharmacology.
[282] B. Fredholm,et al. Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. , 1991, Acta physiologica Scandinavica.
[283] A. IJzerman,et al. 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. , 1991, Journal of medicinal chemistry.
[284] S Schiffmann,et al. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. , 1990, Biochemical and biophysical research communications.
[285] J. Fergus,et al. Structure-activity relationships for enhancement of adenosine A1 receptor binding by 2-amino-3-benzoylthiophenes. , 1990, Molecular pharmacology.
[286] R. Hirschhorn. Adenosine deaminase deficiency. , 1987, Immunodeficiency reviews.
[287] K. Jacobson,et al. Species differences in structure‐activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors , 1986, FEBS letters.
[288] A. Newby. Adenosine and the concept of ‘retaliatory metabolites’ , 1984 .
[289] R F Bruns,et al. Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. , 1980, Canadian journal of physiology and pharmacology.